FDA Shake-Ups & mRNA Funding Cuts | Industry Perspectives with Patrick Jordan
In this episode, John Stanford dives into the latest policy and science headlines - from Dr. Vinay Prasad’s dramatic exit and return to the FDA, to HHS’s $500M cut in mRNA research, to looming pharmaceutical tariffs. Then, we debut our new "Industry Perspectives" segment with NovaQuest Capital’s Patrick Jordan, exploring how regulatory uncertainty, populist pricing policies, and global market dynamics impact biotech innovation.
What do you think about HHS’s decision to pull back on mRNA research?
Could foreign reference pricing harm small biotech companies more than big pharma? And how should…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.